NCT04784442已完成2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 188
- 试验地点
- 1
- 主要终点
- Percent Change in LDL-C From Baseline to Week 12
研究概览
简要总结
The purpose of this study is to assess the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy and safety of ETC-1002(bempedoic acid) 60 mg, 120 mg and 180 mg versus placebo added to ongoing stable statin therapy or other lipid-modifying therapies in Japanese patients with hypercholesterolemia treated for 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have obtained informed consent to all of the observation/examination/evaluation items specified in the protocol
- •Patients must be on stable statin therapy defined as atorvastatin, pitavastatin, rosuvastatin, pravastatin, simvastatin, or fluvastatin daily[and other lipid-modifying therapies(LMTs) if needed] at least 4 weeks(6 weeks for fibrates) prior to screening and above LDL-C control target. Or Patients for statin intolerant must be on stable LMT(s) at least 4 weeks prior to screening and above LDL-C control target. Statin intolerance defined as an inability to tolerate 1 or more statins due to an adverse safety effect that started or increased during statin therapy and resolved or improved when statin therapy was discontinued or decreased. Patients on the lowest or under the dosage of the approved dose of statin or unable to tolerate any statin at any dose were eligible. Patients could continue taking the lowest or under the dosage of the approved dose of statin therapy or taking other LMTs throughout the study provided that it was stable and well tolerated.
- •Fasting mean TG level < 400 mg/dL from measurements at screening
- •Other protocol specific inclusion criteria may apply
排除标准
- •Women who are pregnant or breastfeeding or who have a positive pregnancy test (urine) result at screening or baseline visits
- •Sexually active male subjects or sexually active female subjects of childbearing potential who do not agree to practice 2 different methods of birth control or to remain abstinent during the trial and for 30 days after final IMP administration test (urine) result at screening or baseline visits
- •Patients with homozygous familial hypercholesterolemia (HoFH)
- •Patients with a history or current symptoms of any of the following clinically significant cardiovascular diseases within 3 months prior to screening or before baseline visit
- •Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, stroke, transient ischemic attack, symptomatic carotid artery stenosis, symptomatic peripheral arterial disease, or decompensated heart failure
- •Abdominal aortic aneurysm
- •Unexplained syncope or long-QT syndrome, family history of long-QT syndrome, or risk factors for Torsade de Pointes, such as persistent hypokalemia or second- or third-degree atrioventricular block (except when controlled by medication, etc)
- •Uncontrolled hypertension, defined as follows:
- •Sitting systolic blood pressure after resting 5 minutes of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg at screening
- •Patients with uncontrolled and serious hematologic or coagulation disorders or with Hgb of <10.0 g/dL at screening
- •Patients with type 1 diabetes or uncontrolled type 2 diabetes with hemoglobin A1c (HbA1c) of ≥9% at screening
- •Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of >1.5 × ULN at screening
- •Patients with liver disease or dysfunction, including:
- •Positive serology for hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies at screening
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥3 × ULN and/or total bilirubin of ≥2 × ULN
- •Patients with creatine kinase (CK) elevation( >3 × ULN) at screening
- •Patients with renal dysfunction or nephritic syndrome or a history of nephritis and with estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73m2 at screening
- •Other protocol specific inclusion criteria may apply
研究组 & 干预措施
ETC-1002 180mg
Experimental
干预措施: 180mg of ETC-1002(bempedoic acid) (Drug)
ETC-1002 120mg
Experimental
干预措施: 120mg of ETC-1002(bempedoic acid) (Drug)
ETC-1002 60mg
Experimental
干预措施: 60mg of ETC-1002(bempedoic acid) (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percent Change in LDL-C From Baseline to Week 12
时间窗: Baseline, week12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Day 1. When LDL-C at Week 12 was missing, the missing value was imputed using the last observation carried forward from the start of the IMP administration to 2 days after the final IMP administration.
次要结局
- Proportion of Subjects Whose LDL-C Value Achieve < 70 mg/dL at Week 12(Baseline, week12)
- Percent Change in Total Cholesterol From Baseline to Week 12(Baseline, week12)
- Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 12(Baseline, week12)
- Percent Change in Hemoglobin A1c From Baseline to Week 12(Baseline, week12)
- Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12(Baseline, week12)
- Percent Change in Non-HDL Cholesterol From Baseline to Week 12(Baseline, week12)
- Percent Change in Triglycerides From Baseline to Week 12(Baseline, week12)
- Percent Change in Apolipoprotein B From Baseline to Week 12(Baseline, week12)
- Percent Change in HDL Cholesterol From Baseline to Week 12(Baseline, week12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin IntoleranceHypercholesterolemiaNCT01751984Esperion Therapeutics, Inc.56
已完成
2 期
Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese SubjectsHypercholesterolemiaNCT02055976Pfizer218
已完成
3 期
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)HypercholesterolemiaNCT02107898Sanofi216
已完成
3 期
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of StatinHypercholesterolemiaNCT02584504Sanofi163
已完成
3 期
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and TaiwanHypercholesterolemiaNCT02289963Sanofi199